Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2

  title={Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2},
  author={Qi Zhang and Bin Ju and Jiwan Ge and Jasper Fuk-Woo Chan and Lin Cheng and Ruoke Wang and Weijin Huang and Mengqi Fang and Peng Chen and Bingjie Zhou and Shuo Song and Sisi Shan and Baohua Yan and Senyan Zhang and Xiangyang Ge and Jiazhen Yu and Juanjuan Zhao and Haiyan Wang and Li Liu and Qining Lv and Lili Fu and Xuanling Shi and Kwok Yung Yuen and Lei Liu and Youchun Wang and Zhiwei Chen and Linqi Zhang and Xinquan Wang and Zheng Zhang},
  journal={Nature Communications},
  • Qi Zhang, Bin Ju, +26 authors Zheng Zhang
  • Published 2021
  • Medicine
  • Nature Communications
Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical interventions against COVID-19 disease. However, their common genetic and biologic features remain elusive. Here we interrogate a total of 165 antibodies from eight COVID-19 patients, and find that potent nAbs from different patients have disproportionally high representation of IGHV3-53/3-66 usage, and therefore termed as public antibodies. Crystal structural comparison of these antibodies reveals they share… Expand
3 Citations

Figures from this paper

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species
SARS-CoV-2 variants continue to emerge during the global pandemic and may facilitate escape from current antibody therapies and vaccine protection. Here, we showed that the South African variantExpand
SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage
A panel of 28 SARS-CoV-2 pseudoviruses bearing single or combined mutations found in the spike protein of these three variants, as well as additional nine mutations that within or close by the major antigenic sites in the Spike protein identified in the GISAID database are constructed. Expand
Hybrid immunity improves B cell frequency, antibody potency and breadth against SARS-CoV-2 and variants of concern
To understand the nature of the antibody response to SARS-CoV-2 vaccination, we analyzed at single cell level the B cell responses of five naïve and five convalescent people immunized with theExpand


Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
It is shown that human neutralizing antibodies could be efficiently discovered by high-throughput single B-cell sequencing in response to pandemic infectious diseases. Expand
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
This structural and functional analysis illustrates why mutations at E484 and K417 adversely affect major classes of nAbs to SARS-CoV-2 with consequences for next-generation COVID-19 vaccines. Expand
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
Most anti-S antibodies that were generated in this patient during the first weeks of COVID-19 infection were non-neutralizing and target epitopes outside the RBD. Expand
Structural basis of a shared antibody response to SARS-CoV-2
It is found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein, which is promising for vaccine design. Expand
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
A role for potent neutralizing antibodies (nAbs) in prophylaxis, and potentially therapy, of COVID-19 is suggested, as indicated by maintained weight and low lung viral titers in treated animals, and the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters. Expand
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Mapping studies revealed that the SARS-CoV-2 spike protein contained multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as previously undefined non-RBD epitopes, which provide guidance for vaccine design and are promising candidates for treatment and prevention of COVID-19. Expand
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
A diverse collection of potent neutralizing antibodies against the SARS-CoV-2 spike protein have been isolated from five patients with severe COVID-19 and high serum neutralization titres, suggesting both of these regions at the top of the viral spike are immunogenic. Expand
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
It is shown that functional SARS-CoV-2 S protein variants with mutations in the receptor binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Expand
Potently neutralizing and protective human antibodies against SARS-CoV-2
An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans. Expand
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
One antibody, P2C-1F11, most closely mimics binding of receptor ACE2 and displays the most potent neutralizing activity in vitro, as well as conferring protection against SARS-CoV-2 infection in Ad5-hACE2-sensitized mice. Expand